Sarepta Therapeutics Inc. (SRPT)

63.01
NASDAQ : Health Technology
Prev Close 63.01
Day Low/High 0.00 / 0.00
52 Wk Low/High 28.14 / 68.90
Avg Volume 1.53M
Exchange NASDAQ
Shares Outstanding 64.63M
Market Cap 4.14B
EPS -5.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Focused on Two Sectors

Focused on Two Sectors

If we have a little consolidating action here the buyers will start pushing again.

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

Solid Bioscience planned its IPO for months, but waited until the day before its market debut on Friday, Jan. 26, to tell investors about an FDA hold on its key drug candidate.

In This Booming Stock Market, Think Like a Programmer Not a Critic

In This Booming Stock Market, Think Like a Programmer Not a Critic

What drives the trading action are structural issues, not macroeconomic news events or political drama.

First Duchenne Muscular Dystrophy Patient Dosed In Systemic Microdystrophin Gene Therapy

First Duchenne Muscular Dystrophy Patient Dosed In Systemic Microdystrophin Gene Therapy

Duchenne Organizations Led by Parent Project Muscular Dystrophy Help Fund Next Step in Cutting-Edge Treatment

How Trading Notes Can Increase Your Profits

How Trading Notes Can Increase Your Profits

Inertia is your biggest enemy in this market.

You Can't Reason With a Steamroller

You Can't Reason With a Steamroller

The momentum is crushing everything in its way.

Selling Action Is Upon Us

Selling Action Is Upon Us

There is still a very strong appetite for individual stocks with momentum.

Stock Indexes Manage Another Day of Gains

Stock Indexes Manage Another Day of Gains

If you're not nervous, you're not paying attention.

Market Strength Is Putting Bids Under Everything

Market Strength Is Putting Bids Under Everything

The indices are hitting highs as the market shrugs off yesterday's rotation.

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.

10 Biotech Stocks to Watch in 2018

10 Biotech Stocks to Watch in 2018

There are a variety of players that should be active in the M&A space next year.

Sarepta Therapeutics Is on Track for Further Gains

Sarepta Therapeutics Is on Track for Further Gains

Look for an increase to the low $60s followed by the $75 area longer term.

How to Play This Cooling Momentum

How to Play This Cooling Momentum

We have shifted from a market that was mainly index driven by the FAANG names to one where stock picking is more important.

Sarepta Therapeutics Announces Exercise Of Initial Purchasers' Option To Purchase Additional Convertible Senior Notes Due 2024

Sarepta Therapeutics Announces Exercise Of Initial Purchasers' Option To Purchase Additional Convertible Senior Notes Due 2024

-- Capped call transactions raise the effective conversion price of the notes to $104.88, subject to future adjustments --

Sarepta Therapeutics Prices $475 Million Of Convertible Senior Notes Due 2024

Sarepta Therapeutics Prices $475 Million Of Convertible Senior Notes Due 2024

-- Chief executive officer purchases approximately $2 million of shares of Sarepta's common stock --

Seeing Red and Considering Hedges

Seeing Red and Considering Hedges

Tightening stops, closely watching momentum stocks and considering index shorts as I get more defensive.

Sarepta Rises as FDA Clears Investigational Drug Application -- Biotech Movers

Sarepta Rises as FDA Clears Investigational Drug Application -- Biotech Movers

The Cambridge, Mass.-based firm said Nov. 7 that the U.S. Food and Drug Administration has cleared the investigational new drug application for its peptide phosphorodiamidate morpholino oligomer (PPMO) exon 51 candidate, SRP-5051.

Sarepta Therapeutics Announces FDA Clearance Of IND For The Company's PPMO Exon 51 Candidate, SRP-5051

Sarepta Therapeutics Announces FDA Clearance Of IND For The Company's PPMO Exon 51 Candidate, SRP-5051

-- Sarepta to immediately initiate a Phase 1/2a clinical trial in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51 --

Call a Market Top, Go Ahead, I Dare You

Call a Market Top, Go Ahead, I Dare You

Market's at a high, and so is anxiety.

TheStreet Quant Rating: D (Sell)